Iovance Biotherapeutics, Inc.

Contributing Author

Recent Articles by Iovance Biotherapeutics, Inc.

Apr-17	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA GlobeNewswire
Mar-20	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA GlobeNewswire
Feb-26	Iovance Biotherapeutics to Present at Upcoming Conferences IOVA GlobeNewswire
Feb-24	Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas IOVA +30.80% GlobeNewswire
Feb-24	Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates IOVA +30.80% GlobeNewswire
Feb-20	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA GlobeNewswire
Feb-11	Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026 IOVA GlobeNewswire
Feb-05	Best-in-Class Real-World Data Support Early Amtagvi Treatment in Advanced Melanoma IOVA +7.20% IOVA GlobeNewswire
Jan-16	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA +6.31% GlobeNewswire
Dec-19	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA +12.10% IOVA GlobeNewswire
Nov-21	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA +11.61% IOVA GlobeNewswire
Nov-06	Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results IOVA +27.62% GlobeNewswire
Nov-03	Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) IOVA GlobeNewswire
Oct-23	Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025 IOVA GlobeNewswire
Oct-17	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA +6.42% IOVA GlobeNewswire
Sep-19	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA -6.82% GlobeNewswire
Aug-29	Iovance Biotherapeutics to Present at Upcoming Conferences IOVA GlobeNewswire
Aug-22	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA -5.95% IOVA +5.91% GlobeNewswire
Aug-18	Iovance's Amtagvi (lifileucel) Receives Health Canada Approval for Advanced Melanoma IOVA GlobeNewswire
Aug-07	Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 IOVA -20.08% IOVA GlobeNewswire
Jul-24	Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025 IOVA -17.13% GlobeNewswire
Jul-18	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA +11.66% IOVA GlobeNewswire
Jul-15	Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer IOVA GlobeNewswire
Jul-14	Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi in Patients with Advanced Melanoma IOVA +7.49% GlobeNewswire
Jul-10	Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy IOVA GlobeNewswire
Jun-23	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA -6.57% GlobeNewswire
Jun-10	Iovance Biotherapeutics to Present at Upcoming Conference IOVA +7.69% GlobeNewswire
Jun-02	The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi (lifileucel) in Patients with Advanced Melanoma IOVA GlobeNewswire
May-22	Iovance Announces Five-year Results of Amtagvi (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting IOVA GlobeNewswire
May-16	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA +10.24% IOVA -5.68% GlobeNewswire
May-08	Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025 IOVA -44.79% IOVA GlobeNewswire
May-02	Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025 IOVA +5.11% GlobeNewswire

Iovance Biotherapeutics, Inc.

Recent Articles by Iovance Biotherapeutics, Inc.

Upgrade your Finviz experience